WO2009117150A3 - Méthode de traitement d’un lupus avec des dérivés de céramide - Google Patents

Méthode de traitement d’un lupus avec des dérivés de céramide Download PDF

Info

Publication number
WO2009117150A3
WO2009117150A3 PCT/US2009/001773 US2009001773W WO2009117150A3 WO 2009117150 A3 WO2009117150 A3 WO 2009117150A3 US 2009001773 W US2009001773 W US 2009001773W WO 2009117150 A3 WO2009117150 A3 WO 2009117150A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating lupus
ceramide derivatives
subject
ceramide
derivatives
Prior art date
Application number
PCT/US2009/001773
Other languages
English (en)
Other versions
WO2009117150A2 (fr
Inventor
Yunxiang Zhu
Canwen Jiang
Seng H. Cheng
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of WO2009117150A2 publication Critical patent/WO2009117150A2/fr
Publication of WO2009117150A3 publication Critical patent/WO2009117150A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Abstract

L’invention concerne une méthode de traitement d’un lupus chez un sujet, ladite méthode comprenant l’administration au sujet d’une quantité efficace d’un composé représenté par la formule développée (1) : ou d’un sel pharmaceutiquement acceptable de celui-ci.
PCT/US2009/001773 2008-03-20 2009-03-20 Méthode de traitement d’un lupus avec des dérivés de céramide WO2009117150A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7014508P 2008-03-20 2008-03-20
US61/070,145 2008-03-20

Publications (2)

Publication Number Publication Date
WO2009117150A2 WO2009117150A2 (fr) 2009-09-24
WO2009117150A3 true WO2009117150A3 (fr) 2010-01-14

Family

ID=40642035

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/001773 WO2009117150A2 (fr) 2008-03-20 2009-03-20 Méthode de traitement d’un lupus avec des dérivés de céramide

Country Status (1)

Country Link
WO (1) WO2009117150A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1811991B1 (fr) 2004-11-10 2018-11-07 Genzyme Corporation Traitement du diabete de type 2 en utilisant d'inhibiteurs de la synthese des glycosphingolipides
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
EP2594564B1 (fr) * 2007-05-31 2016-09-28 Genzyme Corporation Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol
KR20160085917A (ko) 2007-10-05 2016-07-18 젠자임 코포레이션 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
US8389517B2 (en) 2008-07-28 2013-03-05 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
CN102271678B (zh) 2008-10-03 2017-06-30 简詹姆公司 2‑酰胺基丙醇型葡糖神经酰胺合成酶抑制剂
SI2796457T1 (sl) * 2009-11-27 2016-10-28 Genzyme Corporation Genz 112638 za zdravljenje Gaucherjeve ali Fabryjeve bolezni v kombinirani terapiji
WO2013059119A1 (fr) * 2011-10-17 2013-04-25 The Regents Of The University Of Michigan Inhibiteurs de la glucosylcéramide synthase et méthodes thérapeutiques à l'aide de ceux-ci
WO2014150043A1 (fr) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibiteurs de l'enzyme udp-glucose : n-acyl-sphingosine glucosyltransférase
WO2015042397A1 (fr) 2013-09-20 2015-03-26 Biomarin Pharmaceutical Inc. Inhibiteurs de la glucosylcéramide synthase pour le traitement de maladies
US10239832B2 (en) 2013-10-29 2019-03-26 Biomarin Pharmaceutical Inc. N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors
WO2016126572A2 (fr) 2015-02-02 2016-08-11 The Regents Of The University Of Michigan Inhibiteurs de la glucosylcéramide synthase et méthodes thérapeutiques les utilisant
EP3268355B1 (fr) * 2015-03-11 2019-06-12 BioMarin Pharmaceutical Inc. Inhibiteurs de la glucosylcéramide synthase pour le traitement de maladies
WO2020193746A1 (fr) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de prédiction de la survie de patients atteints de mélanome
JP2022553107A (ja) 2019-10-23 2022-12-21 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン グルコシルセラミドシンターゼ阻害剤およびそれを使用する治療方法
WO2021221953A1 (fr) 2020-04-28 2021-11-04 The Regents Of The University Of Michigan Inhibiteurs pyridine de la glucosylcéramide synthase et procédés thérapeutiques les utilisant

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09169664A (ja) * 1995-12-20 1997-06-30 Seikagaku Kogyo Co Ltd 分化誘導作用を有する薬剤
US20020156107A1 (en) * 2001-01-10 2002-10-24 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
WO2005063275A1 (fr) * 2003-12-23 2005-07-14 Musc Foundaton For Research Development Methodes et compositions pour la prevention et le traitement de maladies ou de troubles inflammatoires
US20050267094A1 (en) * 2002-04-29 2005-12-01 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2005123055A2 (fr) * 2004-06-14 2005-12-29 Musc Foundation For Research Development Methodes pour traiter des troubles inflammatoires
WO2008011487A2 (fr) * 2006-07-19 2008-01-24 Allergan, Inc. Procédés pour le traitement de la douleur chronique à l'aide de 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, d'amides d'acide 3-benzyl-3-hydroxy-2-amino-propioniques et de composés apparentés
WO2008011478A2 (fr) * 2006-07-19 2008-01-24 Allergan, Inc. Procédés de traitement de douleur chronique utilisant des amides d'acide 3-aryl-3-hydroxy-2-amino-propioniques, amides d'acide 3-hétéroaryl-3-hydroxy-2-amino-propionique et composés connexes
WO2008012555A2 (fr) * 2006-07-27 2008-01-31 Isis Innovation Limited Thérapie par réduction d'épitopes
WO2008150486A2 (fr) * 2007-05-31 2008-12-11 Genzyme Corporation Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09169664A (ja) * 1995-12-20 1997-06-30 Seikagaku Kogyo Co Ltd 分化誘導作用を有する薬剤
US20020156107A1 (en) * 2001-01-10 2002-10-24 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
US20050267094A1 (en) * 2002-04-29 2005-12-01 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2005063275A1 (fr) * 2003-12-23 2005-07-14 Musc Foundaton For Research Development Methodes et compositions pour la prevention et le traitement de maladies ou de troubles inflammatoires
WO2005123055A2 (fr) * 2004-06-14 2005-12-29 Musc Foundation For Research Development Methodes pour traiter des troubles inflammatoires
WO2008011487A2 (fr) * 2006-07-19 2008-01-24 Allergan, Inc. Procédés pour le traitement de la douleur chronique à l'aide de 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, d'amides d'acide 3-benzyl-3-hydroxy-2-amino-propioniques et de composés apparentés
WO2008011478A2 (fr) * 2006-07-19 2008-01-24 Allergan, Inc. Procédés de traitement de douleur chronique utilisant des amides d'acide 3-aryl-3-hydroxy-2-amino-propioniques, amides d'acide 3-hétéroaryl-3-hydroxy-2-amino-propionique et composés connexes
WO2008012555A2 (fr) * 2006-07-27 2008-01-31 Isis Innovation Limited Thérapie par réduction d'épitopes
WO2008150486A2 (fr) * 2007-05-31 2008-12-11 Genzyme Corporation Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol

Also Published As

Publication number Publication date
WO2009117150A2 (fr) 2009-09-24

Similar Documents

Publication Publication Date Title
WO2009117150A3 (fr) Méthode de traitement d’un lupus avec des dérivés de céramide
MX2010003603A (es) Metodo para el tratamiento de enfermedades de riñon poliquisticas con derivados de ceramida.
WO2009026176A3 (fr) Composés de flavononol anti-infectieux et leurs procédés d'utilisation
WO2010093849A3 (fr) Dérivés de la phénylalanine-amide utiles pour le traitement de maladies et états liés à l'insuline
WO2007129195A3 (fr) 4-pyrimidine-5-amino-pyrazoles
WO2008131860A3 (fr) Pyridone-carboxamides, phytoprotecteurs contenant ces composés, procédés pour leur production et leur utilisation
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
MY148703A (en) Polycyclic cinnamide derivatives
WO2008124085A3 (fr) Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2
WO2011066352A8 (fr) Forme amorphe et cristalline de l'hémitartrate de genz 112638 au titre d'inhibiteur de la glucosylcéramide synthétase
UA105229C2 (uk) Фармацевтичний склад
MY150507A (en) Polycyclic compound
WO2010105179A3 (fr) Inhibiteurs de bêta-sécrétase
WO2012116290A3 (fr) Stéroïdes neuroactifs substitués par 17(20)-z-vinylcyano, promédicaments de ceux-ci et procédés de traitement les utilisant
TN2012000248A1 (en) Novel spiropiperidine compounds
WO2012141796A3 (fr) Traitement du cancer de la prostate avec des composés inhibiteurs de hsp90
WO2012099942A3 (fr) Méthodes et compositions pour traitement de syndrome métabolique
WO2008019395A3 (fr) Composés pour améliorer l'apprentissage et la mémoire
WO2008153159A1 (fr) Composé aminé et son utilisation pharmaceutique
WO2012096832A3 (fr) Dérivés de camptothécine inhibiteurs de hdac
WO2010066629A3 (fr) Nouvelles azaindoles
WO2012071369A3 (fr) Antagoniste rbp4 non rétinoïde pour le traitement de la dégénérescence maculaire liée à l'âge et de la maladie de stargardt
WO2008005651A3 (fr) Dérivés d'acide rhodanine-carboxylique cycliques destinés au traitement et à la prévention de la tuberculose
WO2009126861A3 (fr) Composés de triazolopyridine utiles en tant qu'inhibiteurs de dgat1
WO2014102592A3 (fr) Composés de pipéridine de type quinoxaline substituée par oxime et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09723434

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09723434

Country of ref document: EP

Kind code of ref document: A2